2016 Sentara Heart Annual Report

Select Page

Sentara Cardiovascular Research Institute

Over the last decade, the SCRI specialty physician team and uniquely trained registered nurse research coordinators have made significant strides in advancing the understanding and treatment of the No. 1 killer in America: Cardiovascular disease.

As the pre-eminent cardiac research institute in the mid-Atlantic region, Sentara Heart works collaboratively with local institutions, government agencies and biomedical companies on nationally and internationally recognized clinical research trials. We focus our efforts on discovering more effective cardiovascular treatments and protocols while eliminating those that are potentially harmful or not as beneficial. Our ultimate goal is to provide enhanced clinical care that advances patient outcomes and improves the overall health of our community.

Our research touches on every aspect of heart care, including medical devices, heart failure, electrophysiology, cardiac surgery, pulmonary hypertension, cardiac interventional procedures, structural heart disease, and the medical management of coronary artery disease risk factors such as diabetes and high cholesterol.

Collectively, our research nurses coordinate more than 80 clinical trials at any given time, shepherding participants through the entire trial process, providing care during periods of need, and tirelessly advocating for their patients’ well-being.

For more information about current research trials or questions about SCRI, please call (757) 388-5480.

Investigational Research Studies at Sentara Heart

Here is a sampling of some of the clinical trials active at SCRI in 2015.

Amulet
Principal Investigator:
Dr. Paul Mahoney
The AMPLATZER™ Amulet™ Left Atrial Appendage Occluder (Amulet) is intended to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.

Genetic-AF
Principal Investigator:
John Herre, MD
To compare the effects of bucindolol hydrochloride to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.

AXAFA
Principal Investigator:
Dr. Philip Gentlesk
To demonstrate that anticoagulation with the direct factor Xa inhibitor apixaban is not less safe than Vitamin-K-antagonists (VKA) therapy in patients undergoing catheter ablation of non-valvular AF
in the prevention of peri-procedural complications.

Surtavi
Principal Investigators:
Drs. Paul Mahoney and Joseph Newton
To compare the effects of bucindolol hydrochloride to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.

Victoria
Principal Investigator:
Dr. Wayne Old
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven trial of MK-1242 (vericiguat) in subjects with heart failure with reduced ejection fraction (HFrEF).

Enable MRI
Principal Investigator:
Dr. Robert Bernstein
To confirm the safety and effectiveness of the ImageReady™ MR Conditional Defibrillation System when used in the 1.5T MRI environment under the labeled Conditions of Use.

Linq HF
Principal Investigator:
Dr. John Herre
The purpose of the LINQ™ HF study is to characterize Reveal LINQ™ derived data from patients with heart failure by assessing the relationship between changes in LINQ™ derived data and other physiologic parameters with subsequent acute decompensated heart failure (ADHF) events.